Aragen Life Sciences key facts
as of Oct 2026- Operator of a life sciences research agency intended to serve the clinical research and development sectors.
- Aragen Life Sciences is valued at approximately $1.4B as of Oct 2026 (last reported valuation).
- It has raised $126.0M; the latest was Secondary Transaction - Private ($34.6M) in Aug 2025.
- Notable investors include Goldman Sachs Asset Management, Quadria Capital, Avendus Capital, SBI Life Insurance (Mumbai).
- Status: Privately Held (backing).
Aragen Life Sciences's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·Watch Aragen Life Sciences: the Monday email on marks, rounds and moves
Aragen Life Sciences funding rounds
No funding rounds for Aragen Life Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Aragen Life Sciences
4Aragen Life Sciences valuation
Aragen Life Sciences's last reported valuation was $1.4 billion in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Aragen Life Sciences investors
4 investors are on record for Aragen Life Sciences, including Goldman Sachs Asset Management, Quadria Capital, Avendus Capital and SBI Life Insurance (Mumbai).
About Aragen Life Sciences
Operator of a life sciences research agency intended to serve the clinical research and development sectors. The company specializes in drug discovery, clinical development, contract manufacturing, formulation, and informatics services, enabling healthcare institutions to offer a broad spectrum of advanced healthcare products and services.
- Sector
- Healthcare
- HQ
- Hyderabad, India
- Founded
- 2001
- Employees
- 4,500
- Website
- aragen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.